Comparative Pharmacology
Head-to-head clinical analysis: DEMULEN 1 50 28 versus MODEYSO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEMULEN 1 50 28 versus MODEYSO.
DEMULEN 1/50-28 vs MODEYSO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive: Ethinyl estradiol and ethynodiol diacetate suppress gonadotropin secretion (LH, FSH) via negative feedback, inhibiting ovulation. Ethynodiol diacetate also increases cervical mucus viscosity and induces endometrial changes.
The mechanism of action of MODEYSO (elacestrant) is not fully elucidated. Elacestrant is an estrogen receptor antagonist that binds to estrogen receptor alpha (ERα) and degrades it, inhibiting estrogen-mediated signaling and tumor growth in ER-positive breast cancer.
One tablet orally once daily for 28 consecutive days per cycle.
400 mg orally once daily with food
None Documented
None Documented
Ethinylestradiol: terminal elimination half-life ~13-27 hours (mean ~17 hours); ethynodiol diacetate (as norethindrone): terminal elimination half-life ~8-11 hours; clinical context: achieved steady-state within 5-10 days; accumulation not significant due to dose interval.
Terminal half-life approximately 6 days (range 4–10 days) in healthy subjects; supports weekly dosing interval
Ethinylestradiol and ethynodiol diacetate are extensively metabolized; urinary excretion accounts for ~40% of ethinylestradiol metabolites and ~50-60% of ethynodiol diacetate metabolites; fecal excretion accounts for ~30% of ethinylestradiol metabolites and ~35% of ethynodiol diacetate metabolites; biliary excretion contributes to enterohepatic circulation.
Renal excretion unchanged: <1%; biliary/fecal elimination: >99% as unchanged drug
Category C
Category C
Combination Oral Contraceptive
Combination Oral Contraceptive